Regado Biosciences, which is focused on the discovery and development of drugs for cardiovascular indications, announced terms for its IPO on Friday. The Basking Ridge, NJ-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Regado Biosciences would command a fully diluted market value of $219 million. Regado Biosciences, which was founded in 2001, plans to list on the NASDAQ under the symbol RGDO. Regado Biosciences initially filed confidentially on March 1, 2013. Cowen & Company and BMO Capital Markets are the joint bookrunners on the deal.
Should the company be successful in its filing, it plans to list on Nasdaq under the symbol “RGDO.”
Regado has 29 employees, including 17 in the Triangle. The company maintains a lab facility in Durham and an office in Cary.
In the filing, the company revealed that it is on a month-to-month lease on the lab space and that the office lease ends in June.
“We may seek to negotiate new leases or look for additional or alternative space for our operations,” the filing reads.
No comments:
Post a Comment